ReviewJournal of obesity & metabolic syndrome2021
Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
Review in Journal of obesity & metabolic syndrome, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials.Obesity (Silver Spring, Md.) · 2025Pooled it
- The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials.Frontiers in endocrinology · 2023Pooled it
- Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives.Reviews in endocrine & metabolic disorders · 2026Review
- Incretin polyagonists as an alternative to bariatric surgery to manage obesity.World journal of gastrointestinal pathophysiology · 2026Review
- Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Efficacy of Dual Glucagon and GLP-1 Agonists as New Treatments for Type II Diabetes.Mini reviews in medicinal chemistry · 2026Review
- Unraveling the connection between obesity, metabolic syndrome and osteoarthritis risk: a large-observational study.Diabetology & metabolic syndrome · 2025Article
- Synthetic pancreatic lipase inhibitors in obesity treatment: current updates onRSC medicinal chemistry · 2025Review
- Use of obesity medications in a young pediatric patient with optic nerve hypoplasia and severe early-onset obesity: A case report.Obesity pillars · 2025Article
- "Ozempic Face": An Emerging Drug-Related Aesthetic Concern and Its Treatment with Endotissutal Bipolar Radiofrequency (RF)-Our Experience.Journal of clinical medicine · 2025Article
- Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions.International journal of obesity (2005) · 2025Review
- Semaglutide and laparoscopic sleeve gastrectomy in an adolescent with congenital adrenal hyperplasia due to 21-hydroxylase: a case report.Journal of medical case reports · 2025Article
- Glucose-lowering medication associated with weight loss may limit the progression of diabetic neuropathy in type 2 diabetes.Journal of the peripheral nervous system : JPNS · 2024Article
- Structure based exploration of mitochondrial alpha carbonic anhydrase inhibitors as potential leads for anti-obesity drug development.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Review
- New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists.Biomedicines · 2024Review
- Review
- Systematic Myostatin Expression Screening Platform for Identification and Evaluation of Myogenesis-Related Phytogenic in Pigs.Bioengineering (Basel, Switzerland) · 2023Article
- Recent advancements in pharmacological strategies to modulate energy balance for combating obesity.RSC medicinal chemistry · 2023Review
- Effects of FermentedNutrients · 2023Article
- A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved for three of the ultrarare genetic conditions that cause obesity-pro-opiomelanocortin deficiency, proprotein convertase subtilisin and kexin type 1 (an important enzyme in the melanocortin pathway) and leptin receptor deficiency. Setmelanotide marks the first in a personalized medicine approach to obesity. Second, semaglutide 2.4 mg once weekly has been submitted to regulators in the United States and the European Union for approval for patients with obesity (body mass index [BMI] ≥30 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.